Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932046 | 1.00 | NTRK1 (0.44) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4933134 | 1.00 | NTRK1 (0.44) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4935414 | 0.91 | NTRK1 (0.41) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4936237 | 0.91 | NTRK1 (0.41) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4935437 | 0.91 | NTRK1 (0.41) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4934374 | 0.89 | HDAC6 (0.37) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4934387 | 0.89 | HDAC6 (0.37) | NTRK1NTRK2POLBMEN1KMT2A | |
| SCHEMBL4930341 | 0.88 | MAPT (0.40) | NTRK1NTRK2POLBPDE10AHSD17B10 | |
| SCHEMBL4930357 | 0.88 | MAPT (0.40) | NTRK1NTRK2POLBPDE10AHSD17B10 | |
| SCHEMBL4931996 | 0.88 | KDM4E (0.41) | MEN1KMT2APDE10AHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | NTRK1 4781/4885NTRK2 4153/4885POLB 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.